Core Viewpoint - Hangzhou Bangshun Pharmaceutical Co., Ltd. is preparing for an IPO on the Hong Kong Stock Exchange, focusing on developing differentiated oral small molecule drugs for oncology and autoimmune diseases, with a strong emphasis on unmet clinical needs in these areas [2][3]. Company Overview - Bangshun Pharmaceutical was established in May 2020 and is nearing commercialization, specializing in oncology and autoimmune diseases [2]. - The company has developed a pipeline that includes one drug candidate in the New Drug Application (NDA) stage (Bezeixin), one candidate in the registration clinical stage (CX1440), and five candidates in the preclinical stage (CX03, CX12, CX13, CX15, and CX16) [3]. Financial Performance - The company reported revenues of RMB 943,000 in 2024, with no revenue in the first nine months of 2025 [4]. - The total losses for the periods were RMB 88.44 million in 2024 and RMB 66.34 million in the first nine months of 2025 [4]. - Research and development costs were RMB 64.53 million in 2024 and RMB 50.98 million in the first nine months of 2025 [4]. Leadership - The board of directors includes four members, with Li Bangliang serving as the chairman and executive director, bringing over 50 years of experience in the pharmaceutical industry [6]. - Li Yuedong, the executive director and deputy general manager, has over 30 years of experience in the pharmaceutical sector, focusing on commercialization and regulatory affairs [8][9].

Core Viewpoint - Bangshun Pharmaceutical has submitted its main board listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor [1] Company Overview - Established in May 2020, Bangshun Pharmaceutical focuses on the development of innovative oral small molecule drug candidates for oncology and autoimmune diseases [3] - The company has a pipeline that includes one NDA-stage candidate (Bezeixinib), one registration clinical-stage candidate (CX1440), and five preclinical candidates (CX03, CX12, CX13, CX15, and CX16) [3] - Founded by Li Bangliang, former chairman of East China Pharmaceutical, and a core team with extensive industry experience [3] Financial Performance - In 2024, the company reported revenue of 943,000 RMB, with no revenue generated in the first nine months of 2025, marking a 100% decrease compared to the same period in 2024 [4][5] - The net losses for the periods ending in 2024 and the first nine months of 2025 were 88.44 million RMB and 66.34 million RMB, respectively [4][5] - The primary reasons for ongoing losses are attributed to operational expenses, including R&D costs and administrative expenses, as well as changes in the fair value of equity redemption liabilities [5][6] R&D and Market Potential - R&D costs for 2024 and the first nine months of 2025 were 64.53 million RMB and 60.00 million RMB, respectively, driven by accelerated clinical development of core products [6] - The oncology drug market in mainland China is projected to grow from 28.6 billion USD in 2020 to 35.9 billion USD in 2024, with a compound annual growth rate (CAGR) of 5.8%, and is expected to reach 73.4 billion USD by 2030, with a CAGR of 12.6% from 2024 to 2030 [3]

Core Viewpoint - Bangshun Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the exclusive sponsor. The company focuses on oncology and autoimmune diseases, with a pipeline that includes one NDA-stage product, one registration clinical-stage product, and five preclinical candidates [1]. Company Summary - The core product, Bezeqitinib, is a JAK inhibitor expected to be among the first domestically approved treatments for myelofibrosis (MF) in China, with an NDA submitted and approval anticipated in Q2 2026. It is also a leading JAK inhibitor for treating polycythemia vera (PV) in China and essential thrombocythemia (ET) globally [1]. - Another key product, CX1440, is a BTK inhibitor currently in Phase III clinical trials, ranking among the top three globally for treating immune thrombocytopenia (ITP) and among the top two for chronic urticaria (CU) and autoimmune hemolytic anemia (AIHA) [1]. Industry Summary - The Chinese myeloproliferative neoplasm (MPN) market is projected to grow from $900 million in 2024 to $1.6 billion by 2030. The market for autoimmune disease drugs in China is expected to increase from $4.6 billion in 2024 to $18.4 billion by 2030 [1].

Company Overview - Hangzhou Bangshun Pharmaceutical Co., Ltd. (Bangshun Pharmaceutical) is a biotechnology company focused on oncology and autoimmune diseases, with a pipeline that includes one new drug application (NDA) candidate (Bezeixinib), one clinical-stage candidate (CX1440), and five preclinical candidates (CX03, CX12, CX13, CX15, and CX16) [3] - Bezeixinib is expected to be one of the first three domestically approved JAK inhibitors for treating myelofibrosis (MF) in China, with clinical trials ongoing for MF, polycythemia vera (PV), and essential thrombocythemia (ET) [3] - CX1440 is a leading BTK inhibitor for treating immune thrombocytopenia (ITP) and is in Phase III clinical trials, with significant market potential in ITP, chronic urticaria (CU), and autoimmune hemolytic anemia (AIHA) [4] Financial Information - For the fiscal year 2024, Bangshun Pharmaceutical reported revenues of approximately CNY 943,000, with losses of approximately CNY 88.44 million [5][6] - The company has only one customer during the reporting period, and its revenue primarily comes from technology transfers related to preclinical projects [4] Industry Overview - The global market for myeloproliferative neoplasms (MPN) is projected to grow from USD 6.6 billion in 2020 to USD 8.3 billion in 2024, with a compound annual growth rate (CAGR) of 6.0%, and is expected to reach USD 12.7 billion by 2030 [8] - The Chinese MPN drug market is also growing, with a projected increase from USD 700 million in 2020 to USD 900 million in 2024, and expected to reach USD 1.6 billion by 2030 [8] - The market for JAK inhibitors in MF is expected to reach USD 300 million in China by 2024, with a CAGR of 3.5% from 2020 to 2024 [11] - The global market for PV drugs is anticipated to grow from USD 2.1 billion in 2020 to USD 2.7 billion in 2024, with a CAGR of 6.5% [13] - The market for autoimmune disease drugs in China is projected to grow from USD 2.5 billion in 2020 to USD 4.6 billion in 2024, with a CAGR of 15.9% [19]

Group 1 - Hangzhou Bangshun Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange on January 22, with CITIC Securities International as the sole sponsor [1] - The company is a biotechnology firm nearing commercialization, focusing on oncology and autoimmune diseases [1] - Bangshun Pharmaceutical has established a pipeline that includes one drug candidate in the New Drug Application (NDA) stage (Bezafibrate), one drug candidate in the registration clinical stage (CX1440), and five drug candidates in the preclinical stage (CX03, CX12, CX13, CX15, and CX16) [1]

Company Overview - Hangzhou Bangshun Pharmaceutical Co., Ltd. is a biotechnology company focused on oncology and autoimmune diseases, with a pipeline that includes one NDA-stage candidate (Bezeixinib), one registration clinical-stage candidate (CX1440), and five preclinical candidates (CX03, CX12, CX13, CX15, and CX16) [2] - Bezeixinib is expected to be one of the first three domestically approved JAK inhibitors for treating myelofibrosis (MF) in China, with clinical trials ongoing in MF, polycythemia vera (PV), and essential thrombocythemia (ET) [2] - CX1440 is a third-phase clinical BTK inhibitor, ranked among the top three globally for treating immune thrombocytopenia (ITP) and among the top two for chronic urticaria (CU) and autoimmune hemolytic anemia (AIHA) [3] Financial Performance - The company reported revenues of RMB 943,000 for the fiscal year 2024 and the nine months ending September 30, 2024, with no revenue reported for the nine months ending September 30, 2025 [4][6] - Losses for the fiscal year 2024 were approximately RMB 88.44 million, with losses of RMB 66.34 million and RMB 179.33 million for the nine months ending September 30, 2024, and 2025, respectively [5][6] Market Overview - The global MPN drug market is projected to grow from USD 6.6 billion in 2020 to USD 8.3 billion in 2024, with a CAGR of 6.0%, and is expected to reach USD 12.7 billion by 2030 [7] - The Chinese MPN drug market is expected to expand from USD 700 million in 2020 to USD 900 million in 2024, with a CAGR of 6.4%, and is projected to reach USD 1.6 billion by 2030 [7] - The market for ITP drugs in China is anticipated to grow from approximately USD 700 million in 2024 to USD 3.6 billion by 2035, with a CAGR of 15.0% [3] - The autoimmune disease drug market in China is expected to grow from USD 2.5 billion in 2020 to USD 4.6 billion in 2024, with a CAGR of 15.9%, and is projected to reach USD 18.4 billion by 2030 [18]

Group 1 - The core viewpoint of the article is that Hangzhou Bangshun Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor [1] - Bangshun Pharmaceutical is a biotechnology company nearing commercialization, focusing on oncology and autoimmune diseases [1] - The company has established a pipeline that includes one new drug application candidate (Bezeqitinib), one clinical-stage candidate (CX1440), and five preclinical candidates (CX03, CX12, CX13, CX15, and CX16) [1]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Hangzhou Bangshun Pharmaceutical Co., Ltd. 杭州邦順製藥股份有限公司 (the "Company") (A joint stock company established in the P ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Hangzhou Bangshun Pharmaceutical Co., Ltd. 重要提示：閣下如對本文件的任何內容有任何疑問，應徵詢獨立專業意見。 杭州邦順製藥股份有限公司 （「本公司」） （於中華人民共和國成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問或包銷團成員 表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據呈交香港公司註冊處處 長註冊的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的 ...